reference/20646544

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20646544

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase IV\|Journal Article\|Multicenter Study\|Randomized Controlled Trial
endingPage	84
issn	0379-0355
issueIdentifier	9
pageRange	579-84
publicationName	Methods and findings in experimental and clinical pharmacology
startingPage	579
bibliographicCitation	Sánchez-Tapias JM, Crespo J, Diago M, Pérez R, Romero-Gómez M, Muñoz-Sánchez M. Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4. Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):579–84. PMID: 12616704.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e3859e0597bfad50657adcd045e0a07a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c65f7396c3b175b283a5c6b117aece28 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_28422f013b209d1c565f11dddc6baed8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f079c5ad549386e0a7c912cd31d5d28 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bca88171fc2e33b9e588ec04edf0f2a5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_464bb48865603286d10ffdf8c091e69c
date	200211
identifier	https://pubmed.ncbi.nlm.nih.gov/12616704
isPartOf	https://portal.issn.org/resource/ISSN/0379-0355 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5611
language	English
source	https://pubmed.ncbi.nlm.nih.gov/
title	Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4
discusses	http://id.nlm.nih.gov/mesh/M0552528 http://id.nlm.nih.gov/mesh/M0001518 http://id.nlm.nih.gov/mesh/M0017182 http://id.nlm.nih.gov/mesh/M0263641 http://id.nlm.nih.gov/mesh/M0018641 http://id.nlm.nih.gov/mesh/M0374956 http://id.nlm.nih.gov/mesh/M0019062 http://id.nlm.nih.gov/mesh/M0025711
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D012254Q000008 http://id.nlm.nih.gov/mesh/D019698Q000188 http://id.nlm.nih.gov/mesh/D000998Q000008 http://id.nlm.nih.gov/mesh/D016898Q000009 http://id.nlm.nih.gov/mesh/D011092 http://id.nlm.nih.gov/mesh/D016898Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D012254Q000009 http://id.nlm.nih.gov/mesh/D013997 http://id.nlm.nih.gov/mesh/D019698Q000821 http://id.nlm.nih.gov/mesh/D012107 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000077190 http://id.nlm.nih.gov/mesh/D011994 http://id.nlm.nih.gov/mesh/D004359
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID37542 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9601 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10399

Total number of triples: 46.